We are reporting from the 2020 ASCO Virtual Scientic Program!
We have recapped some of the top news that have been presented during the conference—and soon we'll speak with Dr Skip Burris, ASCO president, on the big takeaways from this year’s meeting.
Welcome to OncLive News Network! I’m Gina Columbus.
In patients with biochemically relapsed prostate cancer, imaging with the PSMA-targeting agent18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET in the phase 3 CONDOR trial. The study showed high specificity in detecting lymph node disease involvement and significant positive predictive value in the detection of metastatic disease.
Updated findings of the phase 3 KEYNOTE-426 combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.
In the phase 3 BEACON CRC study, there continued to be an overall survival benefit for encorafenib plus cetuximab with or without binimetinib compared with cetuximab plus irinotecan-containing regimens in patients with BRAF V600E—mutated metastatic colorectal cancer.
Pembrolizumab was found to improve progression-free survival after subsequent therapy for patients with PD-L1—positive, relapsed/refractory head and neck squamous cell carcinoma compared with the standard EXTREME regimen, according to an analysis of the KEYNOTE-048 trial. Moreover, pembrolizumab induced better PFS2 outcomes both as a single agent and in combination with chemotherapy.
In melanoma, findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib and trametinib in patients with resected, stage III BRAF V600E/K-mutant melanoma. The 4- and 5-year relapse-free survival rates were 55% and 52% with the doublet therapy versus 38% and 36% with placebo.
Also in melanoma, the combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600—mutant melanoma, according to an updated analysis of the COLUMBUS trial.
In acute myeloid leukemia, phase I dose-escalation findings showed that the bispecific T-cell engager AMG 330 was safe and tolerable in treating patients with relapsed or refractory disease, with cytokine release syndrome as the most frequent and expected adverse event.
An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma. In the phase 1 multicenter, dose-escalation trial, there was an overall response rate of 21.1%, with 1 complete response, 6 very good partial responses, 9 PRs, and 4 minimal responses.
Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma. 21 out of 52 patients achieved a response, per International Myeloma Working Group criteria. The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma, as seen in the DESTINY-CRC01 and DESTINY-Gastric01 studies, respectivey.
In lung cancer, the addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer, as seen in updated results from the phase 3 CASPIAN study. After a median follow-up of 25.1 months, the median OS was 12.9 months among patients who received durvalumab plus EP compared with 10.5 months for those who received EP alone.
In the phase 3 BGB-A317-307 trial, combining the anti—PD-1 agent tislelizumab with chemotherapy improved progression-free survival versus chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer.
For more coverage of the 2020 ASCO Virtual Scientific Program, please visit onclive.com.
That’s all for today. It has been a pleasure having you on with us for OncLive News Network: On Location at the 2020 ASCO Virtual Scientific Program.
Thank you for watching OncLive News Network! I’m Gina Columbus.